---
title: "Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288107555.md"
description: "Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News"
datetime: "2026-05-29T11:15:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288107555.md)
  - [en](https://longbridge.com/en/news/288107555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288107555.md)
generator: "portal-rs"
---

# Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | VCYT Stock News

### Related Stocks

- [VCYT.US](https://longbridge.com/en/quote/VCYT.US.md)

## Related News & Research

- [Veracyte (NASDAQ:VCYT)  Shares Down 4.5%  After Insider Selling](https://longbridge.com/en/news/298063108.md)
- [Veracyte director Muna Bhanji disposes of 1,864 common shares worth $80,086.08](https://longbridge.com/en/news/297957715.md)
- [Jazz reports Phase III trial interim results for Ziihera combination](https://longbridge.com/en/news/298029886.md)
- [Health Rounds: Psychedelic drug shows promise for preventing chemotherapy-induced nerve damage](https://longbridge.com/en/news/297960476.md)
- [Dogwood Therapeutics highlights Halneuron Phase 2b data readout timeline for chemotherapy-induced neuropathic pain program](https://longbridge.com/en/news/298049944.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**